Evidence map›Paper›PMID 37627612›Full record

ArticleAntioxidants (Basel, Switzerland)2023

Kinetic Effects of Transferrin-Conjugated Gold Nanoparticles on the Antioxidant Glutathione-Thioredoxin Pathway.

Sonia Sebastian, Manuela Klingler Hoffmann, Douglas Howard, Clifford Young, Jenni Washington, Harald Unterweger, Christoph Alexiou, Tyron Turnbull, Richard D'Andrea, Peter Hoffmann and 1 more

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Sonia SebastianFuture Industries Institute, University of South Australia, Adelaide, SA 5095, Australia.
Manuela Klingler HoffmannClinical Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Douglas HowardFuture Industries Institute, University of South Australia, Adelaide, SA 5095, Australia.
Clifford YoungClinical Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Jenni WashingtonClinical Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Harald UnterwegerDepartment of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.ORCID 0000-0002-8335-0692
Christoph AlexiouDepartment of Otorhinolaryngology, Head and Neck Surgery, Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung Professorship, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.ORCID 0000-0003-2220-6790
Tyron TurnbullFuture Industries Institute, University of South Australia, Adelaide, SA 5095, Australia.
Richard D'AndreaCentre for Cancer Biology, University of South Australia, Adelaide, SA 5000, Australia.
Peter HoffmannClinical Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Ivan KempsonFuture Industries Institute, University of South Australia, Adelaide, SA 5095, Australia.ORCID 0000-0002-3886-9516
University of South Australia · AUUniversitätsklinikum Erlangen · DE

Funding

Australian Research Council DP190102119Tour de Cure RSP-253-18/19
6 · The paper itself

Abstract

Nanoparticle-based therapeutics are being clinically translated for treating cancer. Even when thought to be biocompatible, nanoparticles are being increasingly identified as altering cell regulation and homeostasis. Antioxidant pathways are important for maintaining cell redox homeostasis and play important roles by maintaining ROS levels within tolerable ranges. Here, we sought to understand how a model of a relatively inert nanoparticle without any therapeutic agent itself could antagonize a cancer cell lines' antioxidant mechanism. A label-free protein expression approach was used to assess the glutathione-thioredoxin antioxidative pathway in a prostate cancer cell line (PC-3) after exposure to gold nanoparticles conjugated with a targeting moiety (transferrin). The impact of the nanoparticles was also corroborated through morphological analysis with TEM and classification of pro-apoptotic cells by way of the sub-G0/G1 population via the cell cycle and annexin V apoptosis assay. After a two-hour exposure to nanoparticles, major proteins associated with the glutathione-thioredoxin antioxidant pathway were downregulated. However, this response was acute, and in terms of protein expression, cells quickly recovered within 24 h once nanoparticle exposure ceased. The impact on PRDX-family proteins appears as the most influential factor in how these nanoparticles induced an oxidative stress response in the PC-3 cells. An apparent adaptive response was observed if exposure to nanoparticles continued. Acute exposure was observed to have a detrimental effect on cell viability compared to continuously exposed cells. Nanoparticle effects on cell regulation likely provide a compounding therapeutic advantage under some circumstances, in addition to the action of any cytotoxic agents; however, any therapeutic advantage offered by nanoparticles themselves with regard to vulnerabilities specific to the glutathione-thioredoxin antioxidative pathway is highly temporal.

Indexed as

antioxidantglutathione-thioredoxinnanoparticleproteomicsreactive oxygen speciesTEM

Identifiers

PMID37627612
PMCPMC10451790
OpenAlexW4385834943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.